# Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1a4e8e3e
Ticker: OLMA
Company: Olema Pharmaceuticals, Inc.
Source: Olema Pharmaceuticals, Inc.
Published: 2026-07-02 20:30 EST
Original Source URL: https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-inducement-grants-under-nasdaq-listing-49
## Summary

SAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that

## Article Body
SAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that
## Recent Company News
- 2026-07-02 20:30 EST — [Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1a4e8e3e) — Source: Olema Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-evaluate-op-3136-in-combination-with-nubeqar-darolutamide-in-metastatic-castration-resistant-prostate-cancer) — Source: Olema Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting) — Source: Olema Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [Olema Oncology Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-first-quarter-2026-financial-and-operating-results) — Source: Olema Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [Olema Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences) — Source: Olema Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)